Showing results (31-40 of 182) with videos related to

Sort By:
Pageof 19
Expert Opinion on Therapeutic Targets|July 25, 2014
Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorderRafael T de Sousa, Rodrigo Machado-Vieira, Carlos A Zarate, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 18, 2014
BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysisAndré R Brunoni, Chris Baeken, Rodrigo Machado-Vieira, et al.
The Journal of Clinical Psychiatry|April 26, 2008
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorderRodrigo Machado-Vieira, Giacomo Salvadore, David A Luckenbaugh, et al.
Expert Review of Molecular Diagnostics|October 15, 2016
Update on bipolar disorder biomarker candidatesAntonio L Teixeira, Haitham Salem, Benicio N Frey, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 30, 2014
BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: a systematic review and meta-analysisAndré R Brunoni, Chris Baeken, Rodrigo Machado-Vieira, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant DepressionCourtney M Vecera, Alan C Courtes, Gregory Jones, et al.
Current Pharmaceutical Design|May 16, 2009
Targeting glutamatergic signaling for the development of novel therapeutics for mood disordersRodrigo Machado-Vieira, Giacomo Salvadore, Lobna A Ibrahim, et al.
Brain Research Bulletin|June 28, 2011
Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot studyLobna Ibrahim, Wallace Duncan, David A Luckenbaugh, et al.
Pharmaceuticals (Basel, Switzerland)|April 3, 2021
Pharmacogenomics of Lithium Response in Bipolar DisorderCourtney M Vecera, Gabriel R Fries, Lokesh R Shahani, et al.
Journal of Affective Disorders|January 26, 2016
An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorderLeorey N Saligan, David A Luckenbaugh, Elizabeth E Slonena, et al.
Pageof 19